NCT03973229View on ClinicalTrials.gov

Neuroendocrine Risk for PTSD in Women

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

November 11, 2019

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
PTSDTrauma
Interventions
DRUG

Estradiol patch

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

OTHER

Placebo patch

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Trial Locations (1)

30303

Grady Memorial Hospital, Atlanta

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Emory University

OTHER

NCT03973229 - Neuroendocrine Risk for PTSD in Women | Biotech Hunter | Biotech Hunter